iTBS+D-Cycloserine for Youth Suicide

D-Cycloserine is a 1950s tuberculosis antibiotic (Seromycin) getting a second life as a neuroscience tool. At low doses it acts as a partial agonist at the glycine binding site of the NMDA receptor, the switch that gates synaptic plasticity. The University of Calgary is running a small Phase 2 (NCT06121284, n=54) pairing DCS with intermittent theta burst stimulation (iTBS), a rapid form of transcranial magnetic stimulation (TMS) that drives plasticity in prefrontal circuits, to treat active suicidal ideation in emerging adults 18-24 [1]. Suicide is the second leading cause of death in that age band in Canada, and current options act slowly. The bet: DCS amplifies the plasticity iTBS induces, baking in a faster and more durable shift in the cognitive substrates of suicidality. Commercially this is not a deal story. DCS is generic and dirt cheap (RxCUI 3007, ATC J04AB01), and the trial is academic-sponsored. Scientifically it sits inside the broader resurgence of NMDA modulation for depression and suicide that ketamine kicked off. Worth watching as a mechanism probe, not as a near-term revenue line.

D-Cycloserine is an approved drug being repurposed, not a novel compound. It was FDA approved decades ago as Seromycin for tuberculosis (WHO ATC J04AB01) and is widely off-patent. The Calgary trial is Phase 2, academic-sponsored, currently recruiting [1]. No Health Canada or FDA designations have been assigned, and none are expected - this is a single-site Canadian investigator-initiated study with no industry partner and no active IND filed in either jurisdiction. Readout is plausible in late 2026 if recruitment holds, though academic psychiatric trials in this population routinely slip. The Calgary trial is the smaller of two active iTBS+DCS programs. The larger and more informative one is the Alfred/Melbourne COGENT program (NCT05591677, Phase 2), testing the same combination in treatment-resistant depression [2]; registry-listed sample size, status, and primary completion date should be confirmed at the source before catalyst-tracking. COGENT will likely read out first and will give the iTBS+DCS concept its first properly powered look. The repurposing field around DCS is busy but has not produced a registration program. The most-cited augmentation trial in social anxiety - Hofmann et al. 2013, AJP, n=169, 50 mg DCS 1 hour before exposure sessions - found similar response and remission rates between DCS and placebo arms after a full CBT course; the early-fast-improvement signal did not translate into a durable separation [6].

The NMDA receptor is a glutamate-gated ion channel on neurons that acts as a coincidence detector. It opens only when the neuron is simultaneously hit with glutamate signaling and already depolarized. That dual requirement makes it the molecular gatekeeper for synaptic plasticity, the strengthening of connections that underlies learning and memory. Long-term potentiation, the workhorse mechanism for rewiring circuits, depends on NMDA receptor activation [3]. D-Cycloserine binds at the glycine co-agonist site on the NR1/GRIN1 subunit. Glycine has to bind there before glutamate-driven opening can occur - it is a permissive switch. At low doses DCS acts as a partial agonist (flips the switch on, but not as hard as full glycine), which enhances NMDA signaling when endogenous glycine is limiting. At higher doses the partial agonism becomes net antagonist. The therapeutic logic for Calgary: iTBS delivers a brief window of high-frequency stimulation to the dorsolateral prefrontal cortex (DLPFC) - the region behind the forehead involved in planning, mood regulation, and executive control - which is implicated in depression and suicidal cognition. That stimulation should induce LTP-like plasticity. DCS, dosed before the session, primes NMDA receptors to be more responsive, amplifying the plasticity signal. The biology is solid for plasticity in animals and in human TMS-EEG paradigms. The translation to suicide-specific endpoints is much weaker. DCS augmentation of exposure therapy for anxiety has produced mixed results across more than 20 trials, with early positive signals flattening in larger meta-analyses [4][7].

NCT06121284 is a Phase 2 single-site randomized trial at the University of Calgary, target enrollment n=54, currently recruiting [1]. Population: emerging adults 18-24 with active suicidal ideation. The dosing protocol used across the Calgary group's prior iTBS+DCS work is 100 mg oral D-cycloserine (or weight-based 25 mg per 17.5 kg body weight in some studies) administered 60-120 minutes before each iTBS session - this is the dose-timing window the Calgary investigators have validated in their open-label and randomized predecessor trials [8], and is the protocol expected to carry into NCT06121284. The dose was selected to fall in the partial-agonist range; higher serum levels can blunt iTBS-induced plasticity. The PK/PD basis for the combination is therefore not novel: the Calgary group ran a series of MDD-focused iTBS+DCS trials (NCT05081986, NCT03937596, NCT05731323) between 2019-2023 establishing the dose, timing, and that serum DCS levels predict antidepressant effects [8]. NCT06121284 carries that established protocol into the youth-suicide population. Primary endpoint is performance on the Death Implicit Association Test (D-IAT), a reaction-time task measuring implicit associations between self and death-related concepts. That choice is the most consequential design decision in the trial. The D-IAT has correlational evidence linking it to future suicide attempts in some studies, but it has not been established as a regulatory-grade endpoint, and a change in D-IAT does not automatically translate to a change in clinical suicide risk. Standard psychiatric trials use clinician-rated scales like the Columbia-Suicide Severity Rating Scale (C-SSRS) or the MADRS. The sample size (54) is fine for a mechanism-of-action study but cannot support an efficacy claim. Typical designs in this space test iTBS+DCS against iTBS+placebo. The registry-listed primary completion date should be pulled from NCT06121284 directly; academic trials enrolling actively suicidal young adults routinely slip 12-18 months.

The model gives this drug a 5% chance of eventual approval. That figure starts from the historical approval rate for Phase 2 drugs in this area - about 24% - then adjusts based on ten facts about the trial and sponsor. The main factors pulling the estimate down are the sponsor's thin or weak approval record, heavier-than-usual blinding, and weak or limited earlier-phase results; the one factor pushing it up is more secondary endpoints than usual. The remaining facts land near average for this stage, so they leave the number roughly where those key adjustments placed it.

Efficacy risk dominates. The D-IAT primary endpoint is the single biggest weakness. A clean statistically significant effect on D-IAT scores does not credibly translate to reduced suicide attempts, and regulators will not accept it as a registration endpoint. The trial is fundamentally a mechanism probe wearing Phase 2 clothing. DCS-specific efficacy risk runs deeper. The Mataix-Cols et al. 2017 JAMA Psychiatry meta-analysis of DCS augmentation of CBT across anxiety disorders (1047 patients, 21 trials) found no significant overall benefit, with early positive trials failing to survive scaled replication [4]. The Hofmann et al. 2013 social anxiety trial showed the same pattern in a single well-powered RCT: faster early improvement on DCS, but identical response and remission rates at endpoint [6]. Whether iTBS+DCS escapes that pattern is the central scientific question. Dosing matters: the response curve for DCS at the NMDA receptor is biphasic (the dose-response curve rises then falls back - too little does nothing, too much blocks instead of enhances), and timing relative to the iTBS session is sensitive. Wrong dose or wrong timing kills the effect. Safety risk is low. At the 50-100 mg single doses used in psychiatric protocols, DCS has a benign profile. The classic Seromycin toxicities (neuropsychiatric effects, seizures) appear at chronic gram-per-day TB dosing over months, not at single adjunctive doses. Execution risk is real: 54 actively suicidal young adults at one Canadian academic site is operationally hard, with slow recruitment and high dropout. Competitive context: the actual standard-of-care comparators in adult suicidality are clozapine (the only FDA-approved drug for suicide risk reduction, in schizophrenia, on the strength of the InterSePT trial) and lithium (Level 1 evidence for suicide reduction in mood disorders); ketamine/esketamine are the recent additions to the NMDA-modulation space. None of these are direct head-to-head comparators in NCT06121284, but they define the bar for any drug claiming a suicide-specific effect. Commercial risk is the whole story for any approval scenario. DCS is generic, no patent, no pricing power. Who pays to commercialize iTBS+generic-pill?

Noise for a commercial portfolio; signal for a mechanism portfolio. The Calgary trial is too small and uses too soft an endpoint to move a market, but it sits inside a real scientific question: can NMDA co-agonist pharmacology amplify stimulation-induced plasticity into durable behavioral change? The data point to watch is not this trial. It is COGENT (NCT05591677, The Alfred, Melbourne), the properly powered Phase 2 of iTBS+DCS in treatment-resistant depression [2]. Investors building a catalyst calendar should pull the registry-listed primary completion date for NCT05591677 directly - public-source aggregators differ and the date has not been independently verified in this writeup; the same applies to the NCT06121284 primary completion date for the Calgary readout. If COGENT hits on MADRS, the iTBS+DCS concept gets a credibility step-up and the Calgary trial becomes a useful supporting mechanism study. If COGENT misses, the Calgary readout becomes a footnote. There is no commercial entity to long or short here directly. University of Calgary is the sponsor; DCS is generic. Indirect industry exposure runs through the TMS device makers - Neuronetics (NASDAQ: STIM) owns the largest installed base of TMS systems via NeuroStar, but they trade on broader TMS adoption trends, not on DCS combination data. Standard-of-care suicidality comparators sit on clozapine and lithium, not on any DCS combination. Check back when COGENT and Calgary primary completion dates are firmed from the registries.